Article info
PDFCorrespondence
Interleukin-4 as an emerging therapeutic target for IgG4-related disease
- Correspondence to Dr Yuko Kaneko, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan; ykaneko.z6{at}keio.jp
Citation
Interleukin-4 as an emerging therapeutic target for IgG4-related disease
Publication history
- Received January 7, 2020
- Accepted January 10, 2020
- First published January 20, 2020.
Online issue publication
July 13, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.